Fixed-dose drug combinations (FDCs) are pharmaceutical formulations containing two or more active pharmaceutical ingredients combined in a fixed ratio within a single dosage form. The Central Drugs Standard Control Organisation (CDSCO) regulates these combinations to ensure therapeutic rationality and patient safety.

Merits of Fixed-Dose Combinations

Enhanced Therapeutic Efficacy:

• Synergistic action through multiple mechanisms targeting different pathways
• Improved treatment outcomes in chronic diseases like hypertension and diabetes
• Reduced drug resistance development, particularly in tuberculosis and HIV treatment
• Better disease control through complementary drug actions
• Example: Teneligliptin + Metformin combination shows superior glycemic control in Type 2 diabetes patients

Patient Compliance Benefits:

• Reduced pill burden leading to better medication adherence
• Simplified dosing schedules improving treatment compliance
• Lower treatment costs compared to separate medications
• Convenient administration especially for elderly patients
• Improved quality of life through easier medication management

Demerits of Fixed-Dose Combinations

Safety and Clinical Concerns:

• Increased adverse effects due to multiple active ingredients
• Difficulty in identifying specific component causing side effects
• Fixed dosing limitations preventing individual dose optimization
• Contraindication complexities when patients have multiple comorbidities
• Drug interaction risks between combined components

Regulatory and Quality Issues:

• Irrational combinations lacking scientific justification flood the market
• CDSCO banned 35 FDCs in 2024 due to safety concerns and lack of proper approvals
• State-level approvals without central oversight creating regulatory gaps
• Inadequate clinical trials for many marketed combinations
• Quality control challenges in manufacturing multiple APIs together

FDCs represent a double-edged therapeutic tool requiring stringent regulatory oversight. The National Health Policy 2017 emphasizes rational drug use, making proper evaluation of FDCs crucial for India's healthcare objectives.